Similar short-term efficacy of antiretroviral therapy in patients infected with HIV B and non-B subtype strains in France

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 2, 2011, Pages

  Bouchaud, Olivier ^a   Le Moing, Vincent ^b   Simon, François ^c   Ngo Van, Philippe ^d   Perre, Philippe ^e   Hocqueloux, Laurent ^f   Lebouche, Bertrand ^g   Carret, Sophie ^d   Spire, Bruno ^c  

^a AVICENNE HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d Abbott   (France)

^e Centre Hospitalier Departemental   (France)

^f CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^g ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ;

ADULT; ANTIVIRAL SUSCEPTIBILITY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FRANCE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78751616027     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820206a2     Document Type: Letter

References (17)

1. Dray-Spira R, Spire B, Heard I, et al. Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study. AIDS. 2007;21(Suppl 1):5-12.
2. Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002;35:1541-1548.
3. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. 2002;16:1139-1146.
4. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39: 537-544.
5. Kalichman SC, Catz S, Ramachandran B. Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc. 1999;91:439-446.
6. Ironson G, O'Cleirigh C, Fletcher MA, et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med. 2005;67:1013-1021.
7. Ashton E, Vosvick M, Chesney M, et al. Social support and maladaptive coping as predictors of the change in physical health symptoms among persons living with HIV/AIDS. AIDS Patient Care STDS. 2005;19: 587-598.
8. Rey D, Bouhnik AD, Peretti-Watel P, et al. Awareness of non-occupational HIV postex-posure prophylaxis among French people living with HIV: the need for better targeting. AIDS. 2007;21(Suppl 1):71-76.
9. Granjean M, Bourlet T, Berthelot P, et al. Human immunodeficiency virus type 1 subtypes in a cohort of infected patients, Saint-Etienne, France, from 1984 to 2003. Med Mal Infect. 2005;35:82-87.
10. Barin F, Plantier JC, Brand D, et al. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J Med Virol. 2006;78(Suppl 1):13-18.
11. Hamers FF, Devaux I, Alix J, et al. HIV/AIDS in Europe: trends and EU-wide priorities. Euro Surveill. 2006;11:E061123.1.
12. Fleury H, Recordon-Pinson P, Caumont A, et al. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retroviruses. 2003;19:41-47.
13. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003;17:2635-2643.
14. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther. 2005;10: 247-254.
15. Vergne L, Stuyver L, Van Houtte M, et al. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol. 2006;36:43-49.
16. Giordano TP, Guzman D, Clark R, et al. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79.
17. Bouchaud O, Le Moing V, Simon F, et al. Subjects infected with B versus non-B HIV1 subtypes in France: differences in social and demographic conditions, but similar short-term virological outcome on therapy. Presented at: 16th Conference on Retrovirus and Opportunistic Infections (CROI 2009); February 8-11, 2009; Montreal, Canada. (poster B-122/284).